PROCANBID (procainamide hydrochloride) by Pfizer is clinical pharmacology procainamide (pa) increases the effective refractory period of the atria, and to a lesser extent the bundle of his-purkinje system and ventricles of the heart. Approved for documented ventricular arrhythmias, such, that and 1 more indications. First approved in 1996.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
PROCANBID is an oral extended-release formulation of procainamide hydrochloride, a Class IA antiarrhythmic agent approved for documented ventricular arrhythmias. It works by increasing the effective refractory period of cardiac tissue, reducing impulse conduction velocity, and decreasing myocardial excitability to suppress ectopic automaticity.
Product is in late-stage lifecycle approaching loss of exclusivity, suggesting limited commercial expansion and team focus on transition strategy rather than growth initiatives.
CLINICAL PHARMACOLOGY Procainamide (PA) increases the effective refractory period of the atria, and to a lesser extent the bundle of His-Purkinje system and ventricles of the heart. It reduces impulse conduction velocity in the atria, His-Purkinje fibers, and ventricular muscle, but has variable…
Worked on PROCANBID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROCANBID offers minimal career growth opportunity given its LOE-approaching status and minimal linked job count; positions are typically maintenance-focused in managed markets, generics defense, and compliance. Professionals joining this product should expect legacy-brand management responsibilities rather than high-visibility growth initiatives.